OBJECTIVE： To systematically review the effects of triple therapy of aprepitant combined with 5-HT3 receptor antagonist and dexamethasone on the safety and daily life quality of malignant cancer chemotherapy patients， and to provide evidence-based reference in clinic. METHODS： Studies were identified by searching Cochrane Library， PubMed， Embase， WanFang Database， VIP Database， CNKI and CBM， including randomized controlled trials and cohort studies of triple therapy of aprepitant（trial group） vs. 5-HT3 receptor antagonist combined with dexamethasone（control group） for the prevention of chemotherapy-induced nausea and vomiting. After data extraction， quality evaluation of literature was conducted （RCT literature quality evaluation according to Cochrane systematic evaluator manual 5.3， non-RCT literatures with Newcastle-Ottawa Scale）， Meta-analysis was conducted by using Rev Man 5.3.0 software. RESULTS： Totally 21 literatures were included， involving 7 698 patients. The results of Meta-analysis showed that the incidence of fatigue [OR＝0.80， 95％CI（0.67，0.95），P＝0.01]， hiccup [OR＝0.52，95％CI（0.34，0.82），P＝0.004]， constipation [OR＝0.73，95％CI（0.63，0.85），P＜0.001]， other drug-related ADR [OR＝0.79，95％CI（0.66，0.95），P＝0.01] in trial group were significantly lower than control group， with statistical significance. The results of Meta-analysis of functional life index of nausea and vomiting showed that the quality of daily life in trial group was significantly higher than control group [OR＝1.60，95％CI（1.41，1.83）， P＜0.001； MD＝10.64，95％CI（8.10，13.18），P＜0.001]， with statistical significance. CONCLUSIONS： Triple therapy of aprepitant combined with 5-HT3 receptor antagonist and dexamethasone can significantly reduce the occurrence of fatigue， hiccup， constipation and other drug-related ADR during malignant cancer chemotherapy， improve life quality and treatment compliance of patients.